aTYR PHARMA INC (ATYR) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 47.09M USD | Research and Development Expense |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | (m) | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -63.86M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $47.09M | (m) | (m) | $-63.86M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $55.72M | (m) | (m) | $-73.29M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $60.22M | $190.00K | (m) | $-77.63M | (m) | 31694.21% | (m) | (m) | (m) |
| 2025-09-30 | $61.56M | $190.00K | (m) | $-78.65M | (m) | 32397.89% | (m) | (m) | (m) |
| 2025-06-30 | $54.23M | $0.00 | (m) | $-70.05M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $52.82M | $0.00 | (m) | $-67.05M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $54.37M | $235.00K | (m) | $-67.91M | (m) | 23137.02% | (m) | (m) | (m) |
| 2024-09-30 | $54.90M | $235.00K | (m) | $-68.05M | (m) | 23361.28% | (m) | (m) | (m) |
| 2024-06-30 | $50.41M | $588.00K | (m) | $-62.52M | (m) | 8573.30% | (m) | (m) | (m) |
| 2024-03-31 | $46.28M | $588.00K | (m) | $-58.77M | (m) | 7870.41% | (m) | (m) | (m) |
| 2023-12-31 | $42.29M | $353.00K | (m) | $-54.92M | (m) | 11981.02% | (m) | (m) | (m) |
| 2023-09-30 | $44.45M | $10.74M | (m) | $-46.91M | (m) | 413.89% | (m) | (m) | (m) |
| 2023-06-30 | $44.00M | (m) | (m) | $-47.79M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $43.29M | (m) | (m) | $-46.81M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $42.81M | $10.39M | (m) | $-46.40M | (m) | 412.17% | (m) | (m) | (m) |
| 2022-09-30 | $33.85M | (m) | (m) | $-47.09M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $29.12M | (m) | (m) | $-41.33M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $27.64M | (m) | (m) | $-39.19M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $23.26M | (m) | (m) | $-34.02M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $22.01M | (m) | (m) | $-30.32M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $21.48M | (m) | (m) | $-29.10M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $18.19M | (m) | (m) | $-24.97M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $17.29M | $10.46M | (m) | $-15.91M | (m) | 165.38% | (m) | (m) | (m) |
| 2020-09-30 | $16.18M | $8.55M | (m) | $-16.93M | (m) | 189.36% | (m) | (m) | (m) |
| 2020-06-30 | $15.37M | $8.58M | (m) | $-15.92M | (m) | 179.05% | (m) | (m) | (m) |
| 2020-03-31 | $14.32M | $8.49M | (m) | $-15.24M | (m) | 168.72% | (m) | (m) | (m) |
| 2019-12-31 | $14.05M | $422.00K | (m) | $-22.98M | (m) | 3328.91% | (m) | (m) | (m) |
| 2019-09-30 | $14.01M | (m) | (m) | $-22.98M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $14.41M | (m) | (m) | $-24.16M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $17.58M | (m) | (m) | $-28.48M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $20.39M | (m) | (m) | $-32.82M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $22.15M | (m) | (m) | $-38.06M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $25.08M | (m) | (m) | $-42.21M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $27.01M | (m) | (m) | $-44.15M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $30.07M | (m) | (m) | $-47.15M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $33.90M | (m) | (m) | $-48.47M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $37.16M | (m) | (m) | $-51.51M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $40.05M | (m) | (m) | $-55.04M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $42.85M | (m) | (m) | $-57.94M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $46.37M | (m) | (m) | $-61.90M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $43.72M | (m) | (m) | $-59.34M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $39.91M | (m) | (m) | $-54.81M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $34.50M | (m) | (m) | $-47.62M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $16.78M | (m) | (m) | $-23.55M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $13.83M | (m) | (m) | $-19.54M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |